Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331132 | 1.00 | LGALS3 (0.44) | LGALS3LGALS9LGALS1LGALS7; LGALS7BALDH1A1 | |
| SCHEMBL13612938 | 1.00 | LGALS3 (0.44) | LGALS3LGALS9LGALS1LGALS7; LGALS7BALDH1A1 | |
| SCHEMBL4331140 | 1.00 | LGALS3 (0.44) | LGALS3LGALS9LGALS1LGALS7; LGALS7BALDH1A1 | |
| SCHEMBL13612935 | 0.90 | ALDH1A1 (0.40) | LGALS3LGALS9LGALS1LGALS7; LGALS7BALDH1A1 | |
| SCHEMBL12891150 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAA | |
| SCHEMBL13151554 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAA | |
| SCHEMBL4259462 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAA | |
| SCHEMBL13486945 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAA | |
| SCHEMBL13672337 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAA | |
| SCHEMBL2816501 | 0.84 | LGALS3 (0.43) | LGALS3LGALS9LGALS1LGALS7; LGALS7BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227431-B2 | Nucleoside derivatives | HETERO DRUGS LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | HETERO DRUGS LIMITED (IN) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233879-A1 | NOVEL NUCLEOSIDE DERIVATIVES | ENTPD5, PNP, ENTPD1 | LGALS3 1441/4885LGALS9 736/4885LGALS1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.